Novel death receptor excitability multivalent antibody and its application in preparation of anti-tumor drugs

Novel death receptor excitability multivalent antibody and its application in preparation of anti-tumor drugs

  • CN 103,833,853 B
  • Filed: 12/25/2013
  • Issued: 05/17/2019
  • Est. Priority Date: 12/25/2013
  • Status: Active Grant
First Claim
Patent Images

1. death receptor excitability multivalent antibody, it is characterised in that:

  • the same epitope of identification DR4, DR5 pass through the p53 structure of peopleDomain connection, forms tetravalent antibody, so that apoptosis occurs for the tumour cell of inducing expression DR4 and DR5 simultaneously, which includesHeavy chain variable region and light chain variable region, heavy chain variable amino acid sequence is as shown in SEQ ID NO.1, chain variable region amino acid sequenceAs shown in SEQ ID NO.2.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×